Skip to main navigation
Skip to search
Skip to main content
Rutgers, The State University of New Jersey Home
Help & FAQ
Link opens in a new tab
Search content at Rutgers, The State University of New Jersey
Home
Profiles
Research units
Core Facilities
Federal Grants
Research output
Vaginal mucositis related to immunotherapy in endometrial cancer
Jharna M. Patel
, Michael Enich
,
Ruth Stephenson
, Roman Groinsberg
,
Eugenia Girda
Cancer Institute of New Jersey (CINJ), Gynecology Oncology
Research output
:
Contribution to journal
›
Article
›
peer-review
3
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Vaginal mucositis related to immunotherapy in endometrial cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Endometrial Cancer
100%
Vaginal mucositis
100%
Mucositis
75%
Immune Checkpoint Inhibitor Therapy
75%
Gynecologic Malignancies
50%
Immune Checkpoint Inhibitors
50%
Uterine Serous Carcinoma
50%
Patient's Will
25%
Systemic Response
25%
Gabapentin
25%
Solid Tumors
25%
Treatment Protocol
25%
Malignancy
25%
Necrosis
25%
Surgery Patients
25%
Pain Medication
25%
Adverse Events
25%
New Onset
25%
Resection
25%
Paclitaxel
25%
Clinical Manifestations
25%
Carboplatin
25%
Hysterectomy
25%
After Surgery
25%
Conventional Chemotherapy
25%
External Beam Radiotherapy
25%
Pain Management
25%
Vaginal mucosa
25%
Older Women
25%
TRK Inhibitors
25%
Sitting down
25%
Combinational Therapy
25%
6-cycles
25%
Prednisone
25%
2-cycles
25%
All-solid
25%
Systemic Chemotherapy
25%
Pelvic Examination
25%
Salpingo-oophorectomy
25%
Nonradiating
25%
Oxycodone
25%
Vaginal Brachytherapy
25%
Lymphadenectomy
25%
Vaginal Pain
25%
Cutaneous Toxicity
25%
PD-L1 Inhibitor
25%
Vaginal Introitus
25%
Fibrinous
25%
Port Site Recurrence
25%
Perineal Pain
25%
Vaginal Recurrence
25%
Medicine and Dentistry
Immunotherapy
100%
Uterine Cancer
100%
Mucositis
100%
Immune Checkpoint Inhibitor
71%
Cancer
42%
Side Effect
28%
Recurrent Disease
28%
Uterine Serous Carcinoma
28%
Adverse Event
14%
Gabapentin
14%
Solid Malignant Neoplasm
14%
Mouth
14%
Paclitaxel
14%
Carboplatin
14%
Programmed Death-Ligand 1
14%
Necrosis
14%
External Beam Radiotherapy
14%
Sitting
14%
Prednisone
14%
Brachytherapy
14%
Venous Ulcer
14%
Retroperitoneal Lymph Node Dissection
14%
Hysterectomy
14%
Case Presentation
14%
Pelvic Examination
14%
Salpingooophorectomy
14%
Oxycodone
14%
Introitus
14%
Skin Toxicity
14%
Vagina Pain
14%
Vagina Mucosa
14%
Perineal Pain
14%
Diseases
14%
Surgery
14%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Mucosa Inflammation
100%
Endometrium Cancer
100%
Immune Checkpoint Inhibitor
71%
Side Effect
28%
Chemotherapy
28%
Recurrent Disease
28%
Carcinoma
28%
Adverse Event
14%
Gabapentin
14%
Solid Malignant Neoplasm
14%
Carboplatin
14%
Paclitaxel
14%
Necrosis
14%
Skin Toxicity
14%
Ulcer
14%
Prednisone
14%
Oxycodone
14%
Perineal Pain
14%
Vagina Pain
14%
Diseases
14%